department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Carboplatin · pharmadog

pharmadog
drugs
Carboplatin

drug

patient view →

Carboplatin Pfizer

Marketedupdated 2mo ago

by $PFE PFIZER INC

Approved

community read0 votes

all catalysts(2)

phase 2 completion · 2

phase 2 completion

Hackensack Meridian Health Inc — carboplatin (Phase II Trial Completion)

Carboplatin Pfizer

phase 2 completion

Sun Yat-Sen University Hospital 5 — carboplatin (Phase II Trial Completion)

Carboplatin Pfizer

News(0)

no news has mentioned this drug yet

brand

Carboplatin

generic

carboplatin

indication

Metastatic Ovarian Cancer

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 1, 2045

~18.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Apr 1, 2045formulationUS 12427104
Apr 1, 2045formulationUS 12427104
Apr 1, 2045formulationUS 12427104

Data sources

ClinicalTrials.gov

last refreshed 15m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 8

drugcarboplatin6 co-mentions · 6 sources
tagOncology6 co-mentions · 2 sources
tagBreast Cancer4 co-mentions · 1 sources
tagDrug Shortage3 co-mentions · 3 sources
tagPulmonology2 co-mentions · 1 sources
tagNSCLC2 co-mentions · 1 sources
tagApproval2 co-mentions · 1 sources
companyAccord Healthcare Inc1 co-mentions · 1 sources

Trials studying Carboplatin Pfizer

phase2A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancerrecruitingn=520
phase1Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Canceractive not recruitingn=751
phase3A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancerrecruitingn=500
phase1A Study of Sigvotatug Vedotin in Advanced Solid Tumorsrecruitingn=1,006
phase2A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancerrecruitingn=125
phase3Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancerrecruitingn=1,260
phase2Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Caactive not recruitingn=46
phase2Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterationsrecruitingn=252

more trials →